Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolic Events in Cancer Patients: A Meta-analysis of Randomized Controlled Trials

Author(s): Loma Al-Mansouri*, Firas R. AL-Obaidi, Rafid Bashir Altaweel, Enrique Soto-Perez-de-Celis, Hasan Al- Farhan, Noor A Abdullah and Laith Alrubaiy

Volume 20, Issue 1, 2024

Published on: 19 May, 2023

Page: [100 - 105] Pages: 6

DOI: 10.2174/1573394719666230329104611

Price: $65

Abstract

Introduction: Cancer is associated with a higher risk of venous thromboembolic events compared to the general population. About one-fifth of patients diagnosed with venous thromboembolic events have underlying cancer. The guidelines recommend both low molecular weight heparin and direct oral anticoagulants for the prevention and treatment of venous thromboembolic events. Further evidence is required to adequately characterize the exact role of direct oral anticoagulants.

Methods: A systematic review of the literature was done by searching the databases of Medline, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov. The analysis included only randomized controlled trials enrolling adult patients with cancer and venous thromboembolic events comparing low molecular weight heparin versus direct oral anticoagulants. Duration of follow-up of at least 6 months was considered as a minimum. The studies had to assess the risk of thromboembolic recurrence rate, all-cause mortality, and risk of bleeding.

Results: The final search results led to the inclusion of five randomized controlled trials. The analysis showed a similar risk of recurrence of venous thrombotic events (RR 0.71, 95% CI 0.44-1.17; p = 0.18), mortality risk (RR 1.02, 95% CI 0.88-1.17; p = 0.8), and major bleeding (RR 1.05, 95% CI 0.69-1.62; p = 0.81) between the two treatment groups.

Conclusion: The use of direct oral anticoagulants is a feasible and practical option in ambulatory cancer patients with venous thromboembolic events. The efficacy and safety are similar to that of low molecular weight heparin.

« Previous Next »
Graphical Abstract

[1]
Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(S6): 381S-453S.
[http://dx.doi.org/10.1378/chest.08-0656] [PMID: 18574271]
[2]
Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005; 11(8): 663-73.
[http://dx.doi.org/10.18553/jmcp.2005.11.8.663] [PMID: 16194130]
[3]
Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: A review. Oncologist 2017; 22(2): 199-207.
[http://dx.doi.org/10.1634/theoncologist.2016-0214] [PMID: 28174293]
[4]
Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost 2017; 117(2): 219-30.
[http://dx.doi.org/10.1160/TH16-08-0615] [PMID: 27882374]
[5]
Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020; 38(5): 496-520.
[http://dx.doi.org/10.1200/JCO.19.01461] [PMID: 31381464]
[6]
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4(1): 1-9.
[http://dx.doi.org/10.1186/2046-4053-4-1] [PMID: 25554246]
[7]
Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378(7): 615-24.
[http://dx.doi.org/10.1056/NEJMoa1711948] [PMID: 29231094]
[8]
Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa Inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36(20): 2017-23.
[http://dx.doi.org/10.1200/JCO.2018.78.8034] [PMID: 29746227]
[9]
McBane RD II, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 2020; 18(2): 411-21.
[http://dx.doi.org/10.1111/jth.14662] [PMID: 31630479]
[10]
Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382(17): 1599-607.
[http://dx.doi.org/10.1056/NEJMoa1915103] [PMID: 32223112]
[11]
Schrag D, Uno H, Rosovsky RPG, et al. The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial. J Clin Oncol 2021; 39(S15): 12020.
[http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.12020]
[12]
Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349(2): 146-53.
[http://dx.doi.org/10.1056/NEJMoa025313] [PMID: 12853587]
[13]
Lee AYY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA 2015; 314(7): 677-86.
[http://dx.doi.org/10.1001/jama.2015.9243] [PMID: 26284719]
[14]
Ortel TL, Neumann I, Ageno W, et al. American society of hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4(19): 4693-738.
[http://dx.doi.org/10.1182/bloodadvances.2020001830] [PMID: 33007077]
[15]
Lyman GH, Carrier M, Ay C, et al. American society of hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer. Blood Adv 2021; 5(4): 927-74.
[http://dx.doi.org/10.1182/bloodadvances.2020003442] [PMID: 33570602]
[16]
Mariani MV, Magnocavallo M, Straito M, et al. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis. J Thromb Thrombolysis 2021; 51(2): 419-29.
[http://dx.doi.org/10.1007/s11239-020-02304-3] [PMID: 33044735]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy